2-甲基硫基 [ 1,3 ] 恶唑酮[5,4-C]吡啶 | 169205-96-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶唑并吡啶类
• 中文名称: 2-甲基硫基 [ 1,3 ] 恶唑酮[5,4-C]吡啶
• 中文别名: 2-甲基硫基[1,3]恶唑酮[5,4-c]吡啶；2-甲基硫基[1,3]恶唑酮[5,4-C]吡啶
• 英文名称: 2-(Methylthio)oxazolo<5,4-c>pyridine
• 英文别名: 2-methylthio-oxazolo[5,4-c]pyridine；2-methylsulfanyl-oxazolo[5,4-c]pyridine；2-(Methylthio)oxazolo[5,4-c]pyridine；2-methylsulfanyl-[1,3]oxazolo[5,4-c]pyridine
• CAS: 169205-96-3
• 化学式: C₇H₆N₂OS
• mdl: MFCD08447111
• 分子量: 166.203
• InChiKey: DEGNWJBCNBPOPI-UHFFFAOYSA-N

物化性质

• 熔点：
  79-81°C
• 沸点：
  306.2±34.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  64.2
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-甲基硫基 [ 1,3 ] 恶唑酮[5,4-C]吡啶 在 palladium on activated charcoal 盐酸 、 甲醇 、 甲酸铵 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 异丙醇 为溶剂， 反应 16.5h， 生成 (R)-1-[4-((S)-3-Methyl-4-oxazolo[5,4-c]pyridin-2-yl-piperazin-1-yl)-pyrimidin-2-yl]-ethanol
  参考文献：
  名称：

  Orally-Effective, Long-Acting Sorbitol Dehydrogenase Inhibitors:  Synthesis, Structure−Activity Relationships, and in Vivo Evaluations of Novel Heterocycle-Substituted Piperazino-Pyrimidines

  摘要：

  Optimization of a previously disclosed sorbitol dehydrogenase inhibitor (SDI, II) for potency and duration of action was achieved by replacing the metabolically labile N,N-dimethylsulfamoyl group with a variety of heterocycles. Specifically, this effort led to a series of novel, in vitro potent SDIs with longer serum half-lives and acceptable in vivo activity in acutely diabetic rats (e.g., 62, 67, and 69). However, the desired in vivo potency in chronically diabetic rats, ED90 less than or equal to 5 mg/kg/day, was achieved only through further modification of the piperazine linker. Several members of this family, including 86, showed better than the targeted potency with ED90 values of 1-2 mg/kg/day. Compound 86 was further profiled and found to be a selective inhibitor of sorbitol dehydrogenase, with excellent pharmacodynamic/pharmacokinetic properties, demonstrating normalization of sciatic nerve fructose in a chronically diabetic rat model for similar to17 h, when administered orally at a single dose of 2 mg/kg/day.

  DOI：

  10.1021/jm010440g
• 作为产物：
  描述：

  3-羟基-4-氨基吡啶 在 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 2-甲基硫基 [ 1,3 ] 恶唑酮[5,4-C]吡啶
  参考文献：
  名称：

  非咪唑组胺H3配体。第三部分 作为非咪唑组胺H3拮抗剂的新型4-正丙基哌嗪。

  摘要：

  为了寻找新的非咪唑组胺H3受体拮抗剂，一系列的1 [（（2-噻唑并吡啶）-4-正丙基]哌嗪，类似的1-[（（2-恶唑并吡啶）-4-正丙基]]制备了哌嗪，1-[（（2-苯并噻唑）-4-正丙基]哌嗪和1-[（（2-苯并恶唑）4-正丙基]哌嗪，并在体外对其作为H3受体拮抗剂进行了测试（电诱发的收缩）豚鼠空肠）。通过比较同源对，噻唑洛衍生物似乎比它们的恶唑类似物具有更高的活性。这些系列中最有效的化合物是1-（2-噻唑并[4,5-c]吡啶）-4-正丙基哌嗪（3c），pA2 = 7.25（其恶唑类似物（4g）显示pA2 = 6.9）。

  DOI：

  10.1016/j.ejmech.2004.09.010

文献信息

• Pharmaceutical composition for the treatment of CNS and other disorders
  申请人：——

  公开号：US20020086871A1

  公开（公告）日：2002-07-04

  The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant &agr;7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant &agr;7 nicotinic receptor agonist.

  本发明涉及一种治疗哺乳动物中枢神经系统（CNS）和其他疾病的方法，包括人类，在哺乳动物中给予一种穿透中枢神经系统的α7烟碱受体激动剂。同时涉及含有药用可接受载体和穿透中枢神经系统的α7烟碱受体激动剂的药物组合物。
• Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
  申请人：Binggeli Alfred

  公开号：US20070093521A1

  公开（公告）日：2007-04-26

  This invention is concerned with compounds of the formula wherein X, A, B, R 1 , R 2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及以下式子的化合物：其中X、A、B、R1、R2和G的定义如说明书和权利要求中所述，并且其药学上可接受的盐。本发明还涉及含有这种化合物的制药组合物、它们的制备过程以及它们用于治疗和/或预防与调节SST受体亚型5相关的疾病的用途。
• Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
  申请人：Gao Yang

  公开号：US20070232591A1

  公开（公告）日：2007-10-04

  Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues of the Formula: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

  提供了式子中描述的Piperazinyl oxoalkyl tetrahydroisoquinolines和相关类似物，其中变量如此处所述。这些化合物可用于调节体内或体外的组胺H3受体的配体结合，并且在治疗人类、驯养伴侣动物和家畜动物的各种中枢神经系统（CNS）和其他疾病方面特别有用。此处提供的化合物可以单独或与一种或多种其他CNS药物联合使用，以增强其他CNS药物的效果。提供了用于治疗此类疾病的制药组合物和方法，以及用于检测组胺H3受体（例如受体定位研究）的配体的方法。
• PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS AND OTHER DISORDERS
  申请人：O'Neill Thomas Brian

  公开号：US20070099904A1

  公开（公告）日：2007-05-03

  The present invention relates to compounds of formula I The substituent designations are as disclosed. At least one of B Q, D and E is nitrogen. The present invention also provides a method of treating disorders of the Central Nervous System such as schizophrenia and cognitive dysfunction.

  本发明涉及I式化合物。取代基的标识如所披露的那样。B、Q、D和E中至少有一个是氮。本发明还提供了一种治疗中枢神经系统疾病，如精神分裂症和认知功能障碍的方法。
• PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES
  申请人：Gao Yang

  公开号：US20110082130A1

  公开（公告）日：2011-04-07

  Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues of the Formula: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

  本文提供了公式中所述的哌嗪氧代烷基四氢异喹啉及其相关类似物，其中变量如本文所述。这些化合物可用于在体内或体外调节组胺H3受体的配体结合，并且在治疗人类、驯养宠物和家畜动物的各种中枢神经系统（CNS）和其他疾病方面特别有用。本文提供的化合物可以单独或与一个或多个其他CNS药物联合使用，以增强其他CNS药物的效果。还提供了用于治疗此类疾病的制药组合物和方法，以及用于检测组胺H3受体（例如受体定位研究）的配体的方法。